AMSTERDAM--(BUSINESS WIRE)--Synaffix BV, a biotechnology company exclusively focused on the development of an industry-leading antibody-drug conjugate (ADC) technology, today announced that its newly constructed high potency laboratory is now fully operational.
The high potency laboratory is designed to facilitate the synthetic modification and safe handling of the most potent anti-cancer payloads and their site-specific attachment to antibodies. This recent advancement enables Synaffix to generate gram-scale batches of ADCs for preclinical use.
